Clinical Trial Update: Description of Neurocognitive and Psychiatric Disorders Associated With Targeted Therapies Used in the Treatment of Lung Cancers With ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway

View source ↗

Summary

This clinical trial update outlines a study examining neurocognitive and psychiatric side effects of ALK/ROS1-targeted therapies in metastatic lung cancer and h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer with Alk Gene Rearrangement
• Non-small Cell Lung Cancer with Ros1 Gene Rearrangement

Drugs mentioned

• ALK inhibitors and ROS1 inhibitors

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Metastatic Lung Cancer, Metastatic Lung Cancer With ALK/ROS1 Fusion | Status: RECRUITING